KCT0001198已完成未知
A multi-center, randomized, double-blind Phase III clinical trial to assess the immunogenicity and safety of NBP607 (Trivalent Inactivated Cell Culture-derived Influenza Vaccine) in healthy adults and elderly subjects
SK Chemicals0 个研究点目标入组 1,155 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Healthy adults aged 19 years or older.
- •2) The subjects who gave written consent to participate in the study voluntarily and are able to comply with all study requirements.
- •3) If female and capable of bearing children,subject has a negative urine pregnancy test result on screening and agrees to employ adequate birth control measures through the study period.
排除标准
- •1) Subjects who are hypersensitive to any component of vaccine, i.e., eggs, chicken or chicken products.
- •2) Subjects with immune deficiency disorder.
- •3) Prior personal history of Guillain-Barre syndrome.
- •4) Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.
- •5) Subjects who experienced fever within 24 hours before vaccination or with the febrile disease(exceeding 38.0?) on screening day or with any acute respiratory infection.
- •6) Subjects who had received immunosuppressant or immune modifying drug within 3 months before screening.
- •7) Subjects who had received blood products or immunoglobulin within 3 months before screening.
- •8) Subjects who had received influenza vaccination within 6 months prior to the screening.
- •9) Subjects who had received other vaccination within a month before screening, or those who had another vaccination scheduled within a month after vaccination with the investigational product.
- •10) Subjects who had participated in other clinical trial within 4 weeks prior to vaccination with the investigational product.
- •11) Subjects who had done blood donation within a week prior to vaccination with the investigational product or are planning to within 7 months.
- •12) Subjects with clinically significant chronic disease or malignant cancer.
- •13) Pregnant women, breast-feeding women.
- •14) Subjects with other clinically significant medical or psychological condition, who in the investigator's opinion may not suitable in participating in the study.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung CancerRecurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.MedDRA version: 18.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002161-30-GRBoehringer Ingelheim International GmbH660
进行中（未招募）
1 期
A study evaluating the efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung CancerRecurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002161-30-HUBoehringer Ingelheim International GmbH671
进行中（未招募）
1 期
A study evaluating the efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung CancerRecurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002161-30-HRBoehringer Ingelheim International GmbH1,030
暂停
3 期
Biosimilar Study on Lung CancerCTRI/2016/06/007041Boehringer Ingelheim India Pvt Ltd660
进行中（未招募）
1 期
A study evaluating the efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung CancerRecurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002161-30-PTBoehringer Ingelheim International GmbH1,030